Literature DB >> 27734811

Amyloid Aβ 42, a promoter of magnetite nanoparticle formation in Alzheimer's disease.

Islam Bogachan Tahirbegi1, Wilmer Alfonso Pardo, Margarita Alvira, Mònica Mir, Josep Samitier.   

Abstract

The accumulation of iron oxides-mainly magnetite-with amyloid peptide is a key process in the development of Alzheimer's disease (AD). However, the mechanism for biogeneration of magnetite inside the brain of someone with AD is still unclear. The iron-storing protein ferritin has been identified as the main magnetite-storing molecule. However, accumulations of magnetite in AD are not correlated with an increase in ferritin, leaving this question unresolved. Here we demonstrate the key role of amyloid peptide Aβ 42, one of the main hallmarks of AD, in the generation of magnetite nanoparticles in the absence of ferritin. The capacity of amyloid peptide to bind and concentrate iron hydroxides, the basis for the formation of magnetite, benefits the spontaneous synthesis of these nanoparticles, even under unfavorable conditions for their formation. Using scanning and transmission electron microscopy, electron energy loss spectroscopy and magnetic force microscopy we characterized the capacity of amyloid peptide Aβ 42 to promote magnetite formation.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27734811     DOI: 10.1088/0957-4484/27/46/465102

Source DB:  PubMed          Journal:  Nanotechnology        ISSN: 0957-4484            Impact factor:   3.874


  9 in total

Review 1.  Treating Alzheimer's disease by targeting iron.

Authors:  Sara Nikseresht; Ashley I Bush; Scott Ayton
Journal:  Br J Pharmacol       Date:  2019-02-11       Impact factor: 8.739

2.  Iron Oxide Nanoparticles Induces Cell Cycle-Dependent Neuronal Apoptosis in Mice.

Authors:  Vijayprakash Manickam; Vasanth Dhakshinamoorthy; Ekambaram Perumal
Journal:  J Mol Neurosci       Date:  2018-01-24       Impact factor: 3.444

Review 3.  The neuroprotective effects of glucagon-like peptide 1 in Alzheimer's and Parkinson's disease: An in-depth review.

Authors:  Niklas Reich; Christian Hölscher
Journal:  Front Neurosci       Date:  2022-09-01       Impact factor: 5.152

Review 4.  Delineation of Neuroprotective Effects and Possible Benefits of AntioxidantsTherapy for the Treatment of Alzheimer's Diseases by Targeting Mitochondrial-Derived Reactive Oxygen Species: Bench to Bedside.

Authors:  Vaibhav Walia; Deepak Kaushik; Vineet Mittal; Kuldeep Kumar; Ravinder Verma; Jatin Parashar; Rokeya Akter; Md Habibur Rahman; Saurabh Bhatia; Ahmed Al-Harrasi; Chenmala Karthika; Tanima Bhattacharya; Hitesh Chopra; Ghulam Md Ashraf
Journal:  Mol Neurobiol       Date:  2021-11-09       Impact factor: 5.682

5.  Fe(II) formation after interaction of the amyloid β-peptide with iron-storage protein ferritin.

Authors:  Lucia Balejcikova; Katarina Siposova; Peter Kopcansky; Ivo Safarik
Journal:  J Biol Phys       Date:  2018-05-09       Impact factor: 1.365

6.  Evaluating effect of metallic ions on aggregation behavior of β-amyloid peptides by atomic force microscope and surface-enhanced Raman Scattering.

Authors:  Yang Xie; Lin Yu; Yuna Fu; Heng Sun; Jianhua Wang
Journal:  Biomed Eng Online       Date:  2021-12-30       Impact factor: 2.819

Review 7.  Challenges and Opportunities of Deferoxamine Delivery for Treatment of Alzheimer's Disease, Parkinson's Disease, and Intracerebral Hemorrhage.

Authors:  Amy Corbin Farr; May P Xiong
Journal:  Mol Pharm       Date:  2020-10-09       Impact factor: 4.939

8.  Quantitative comparison of different iron forms in the temporal cortex of Alzheimer patients and control subjects.

Authors:  Marjolein Bulk; Louise van der Weerd; Wico Breimer; Nikita Lebedev; Andrew Webb; Jelle J Goeman; Roberta J Ward; Martina Huber; Tjerk H Oosterkamp; Lucia Bossoni
Journal:  Sci Rep       Date:  2018-05-02       Impact factor: 4.379

Review 9.  Iron and Alzheimer's Disease: From Pathogenesis to Therapeutic Implications.

Authors:  Jun-Lin Liu; Yong-Gang Fan; Zheng-Sheng Yang; Zhan-You Wang; Chuang Guo
Journal:  Front Neurosci       Date:  2018-09-10       Impact factor: 4.677

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.